AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
19.47
-0.11 (-0.56%)
May 9, 2025, 1:15 PM - Market open
AnaptysBio Revenue
AnaptysBio had revenue of $27.77M in the quarter ending March 31, 2025, with 286.84% growth. This brings the company's revenue in the last twelve months to $111.87M, up 387.20% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$111.87M
Revenue Growth
+387.20%
P/S Ratio
5.14
Revenue / Employee
$822,588
Employees
136
Market Cap
572.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ANAB News
- 3 days ago - Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Stock Repurchase Plan - GlobeNewsWire
- 2 months ago - Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Anaptys Announces Participation in March Investor Conferences - GlobeNewsWire
- 3 months ago - Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - GlobeNewsWire
- 3 months ago - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - GlobeNewsWire
- 3 months ago - Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - GlobeNewsWire